inclusion criteria 1. diagnosis of a sard (rheumatoid arthritis, systemic lupus erythematosus (sle), juvenile inflammatory arthritis, systemic sclerosis (ssc), idiopathic inflammatory myositis (iim), overlap connective tissue diseases, mixed connective tissue disease, undifferentiated connective tissue diseases, giant-cell arteritis, and the anca-associated vasculitis: granulomatosis with polyangiitis (gpa; formerly known as wegener's granulomatosis), microscopic polyangiitis (mpa), and eosinophilic granulomatosis with polyangiitis (egpa; previously known as churg-strauss syndrome); 2. has received 3 or more doses of an mrna vaccine; 3. age 18 years and older; 4. male or non-pregnant female; 5. rituximab treatment within last 12 months; 6. able to comprehend the study protocol and provide informed consent. exclusion criteria 1. any medical disease or condition that, in the opinion of the site principal investigator or sub-investigator, precludes study participation; 2. significant behavioral disturbances; 3. previous diagnosis of hepatitis b, hepatitis c or hiv; 4. history of hypersensitivity or severe allergic reaction such as anaphylaxis to a component of the vaccine or to a previous vaccine; 5. people who experienced inflammation of the heart or lining of the heart (myocarditis or pericarditis) after a previous dose of an mrna vaccine or protein subunit vaccine.

inclusion criteria 1. diagnosis of a sard (rheumatoid arthritis, systemic lupus erythematosus (sle), juvenile inflammatory arthritis, systemic sclerosis (ssc), idiopathic inflammatory myositis (iim), overlap connective tissue diseases, mixed connective tissue disease, undifferentiated connective tissue diseases, giant-cell arteritis, and the anca-associated vasculitis: granulomatosis with polyangiitis (gpa; formerly known as wegener's granulomatosis), microscopic polyangiitis (mpa), and eosinophilic granulomatosis with polyangiitis (egpa; previously known as churg-strauss syndrome); 2. has received 3 or more doses of an mrna vaccine; 3. age 18 years and older; 4. male or non-pregnant female; 5. rituximab treatment within last 12 months; 6. able to comprehend the study protocol and provide informed consent. exclusion criteria 1. any medical disease or condition that, in the opinion of the site principal investigator or sub-investigator, precludes study participation; 2. significant behavioral disturbances; 3. previous diagnosis of hepatitis b, hepatitis c or hiv; 4. history of hypersensitivity or severe allergic reaction such as anaphylaxis to a component of the vaccine or to a previous vaccine; 5. people who experienced inflammation of the heart or lining of the heart (myocarditis or pericarditis) after a previous dose of an mrna vaccine or protein subunit vaccine.

inclusion criteria diagnosis of a sard (rheumatoid arthritis, systemic lupus erythematosus (sle), juvenile inflammatory arthritis, systemic sclerosis (ssc), idiopathic inflammatory myositis (iim), overlap connective tissue diseases, mixed connective tissue disease, undifferentiated connective tissue diseases, giant-cell arteritis, and the anca-associated vasculitis: granulomatosis with polyangiitis (gpa; formerly known as wegener's granulomatosis), microscopic polyangiitis (mpa), and eosinophilic granulomatosis with polyangiitis (egpa; previously known as churg-strauss syndrome); has received 3 or more doses of an mrna vaccine; age 18 years and older; male or non-pregnant female; rituximab treatment within last 12 months; able to comprehend the study protocol and provide informed consent. exclusion criteria any medical disease or condition that, in the opinion of the site principal investigator or sub-investigator, precludes study participation; significant behavioral disturbances; previous diagnosis of hepatitis b, hepatitis c or hiv; history of hypersensitivity or severe allergic reaction such as anaphylaxis to a component of the vaccine or to a previous vaccine; people who experienced inflammation of the heart or lining of the heart (myocarditis or pericarditis) after a previous dose of an mrna vaccine or protein subunit vaccine.

inclusion criteria diagnosis of a sard (rheumatoid arthritis, systemic lupus erythematosus (sle), juvenile inflammatory arthritis, systemic sclerosis (ssc), idiopathic inflammatory myositis (iim), overlap connective tissue diseases, mixed connective tissue disease, undifferentiated connective tissue diseases, giant-cell arteritis, and the anca-associated vasculitis: granulomatosis with polyangiitis (gpa; formerly known as wegener's granulomatosis), microscopic polyangiitis (mpa), and eosinophilic granulomatosis with polyangiitis (egpa; previously known as churg-strauss syndrome); has received 3 or more doses of an mrna vaccine; age 18 years and older; male or non-pregnant female; rituximab treatment within last 12 months; able to comprehend the study protocol and provide informed consent. exclusion criteria any medical disease or condition that, in the opinion of the site principal investigator or sub-investigator, precludes study participation; significant behavioral disturbances; previous diagnosis of hepatitis b, hepatitis c or hiv; history of hypersensitivity or severe allergic reaction such as anaphylaxis to a component of the vaccine or to a previous vaccine; people who experienced inflammation of the heart or lining of the heart (myocarditis or pericarditis) after a previous dose of an mrna vaccine or protein subunit vaccine.

inclusion criteria diagnosis of a sard (rheumatoid arthritis, systemic lupus erythematosus (sle), juvenile inflammatory arthritis, systemic sclerosis (ssc), idiopathic inflammatory myositis (iim), overlap connective tissue diseases, mixed connective tissue disease, undifferentiated connective tissue diseases, giant-cell arteritis, and the anca- associated vasculitis: granulomatosis with polyangiitis (gpa; formerly known as wegener's granulomatosis), microscopic polyangiitis (mpa), and eosinophilic granulomatosis with polyangiitis (egpa; previously known as churg-strauss syndrome); has received 3 or more doses of an mrna vaccine; age 18 years and older; male or non-pregnant female; rituximab treatment within last 12 months; able to comprehend the study protocol and provide informed consent. exclusion criteria any medical disease or condition that, in the opinion of the site principal investigator or sub-investigator, precludes study participation; significant behavioral disturbances; previous diagnosis of hepatitis b, hepatitis c or hiv; acute illness, with or without fever within 72 hours prior to vaccination; history of hypersensitivity or severe allergic reaction such as anaphylaxis to a component of the vaccine or to a previous vaccine; any vaccine received in the 30 days prior to the fourth or fifth dose of covid-19 vaccine; any vaccine scheduled to be received in the 30 days following the administration of the fourth or fifth dose of covid-19 vaccine and that cannot be postponed; people who experienced inflammation of the heart or lining of the heart (myocarditis or pericarditis) after a previous dose of an mrna vaccine or protein subunit vaccine.

inclusion criteria diagnosis of a sard (rheumatoid arthritis, systemic lupus erythematosus (sle), juvenile inflammatory arthritis, systemic sclerosis (ssc), idiopathic inflammatory myositis (iim), overlap connective tissue diseases, mixed connective tissue disease, undifferentiated connective tissue diseases, giant-cell arteritis, and the anca- associated vasculitis: granulomatosis with polyangiitis (gpa; formerly known as wegener's granulomatosis), microscopic polyangiitis (mpa), and eosinophilic granulomatosis with polyangiitis (egpa; previously known as churg-strauss syndrome); has received 3 or more doses of an mrna vaccine; age 18 years and older; male or non-pregnant female; rituximab treatment within last 12 months; able to comprehend the study protocol and provide informed consent. exclusion criteria any medical disease or condition that, in the opinion of the site principal investigator or sub-investigator, precludes study participation; significant behavioral disturbances; previous diagnosis of hepatitis b, hepatitis c or hiv; acute illness, with or without fever within 72 hours prior to vaccination; history of hypersensitivity or severe allergic reaction such as anaphylaxis to a component of the vaccine or to a previous vaccine; any vaccine received in the 30 days prior to the fourth or fifth dose of covid-19 vaccine; any vaccine scheduled to be received in the 30 days following the administration of the fourth or fifth dose of covid-19 vaccine and that cannot be postponed; people who experienced inflammation of the heart or lining of the heart (myocarditis or pericarditis) after a previous dose of an mrna vaccine or protein subunit vaccine.

inclusion criteria diagnosis of a sard (rheumatoid arthritis, systemic lupus erythematosus (sle), juvenile inflammatory arthritis, systemic sclerosis (ssc), idiopathic inflammatory myositis (iim), overlap connective tissue diseases, mixed connective tissue disease, undifferentiated connective tissue diseases, giant-cell arteritis, and the anca-associated vasculitis: granulomatosis with polyangiitis (gpa; formerly known as wegener's granulomatosis), microscopic polyangiitis (mpa), and eosinophilic granulomatosis with polyangiitis (egpa; previously known as churg-strauss syndrome); has received 3 or 4 doses of an mrna vaccine; age 18 years and older; male or non-pregnant female; rituximab treatment within last 12 months; able to comprehend the study protocol and provide informed consent. exclusion criteria any medical disease or condition that, in the opinion of the site principal investigator or sub-investigator, precludes study participation; significant behavioral disturbances; previous diagnosis of hepatitis b, hepatitis c or hiv; acute illness, with or without fever within 72 hours prior to vaccination; history of hypersensitivity or severe allergic reaction such as anaphylaxis to a component of the vaccine or to a previous vaccine; any vaccine received in the 30 days prior to the fourth or fifth dose of covid-19 vaccine; any vaccine scheduled to be received in the 30 days following the administration of the fourth or fifth dose of covid-19 vaccine and that cannot be postponed; people who experienced inflammation of the heart or lining of the heart (myocarditis or pericarditis) after a previous dose of an mrna vaccine or protein subunit vaccine. ne;

inclusion criteria diagnosis of a sard (rheumatoid arthritis, systemic lupus erythematosus (sle), juvenile inflammatory arthritis, systemic sclerosis (ssc), idiopathic inflammatory myositis (iim), overlap connective tissue diseases, mixed connective tissue disease, undifferentiated connective tissue diseases, giant-cell arteritis, and the anca-associated vasculitis: granulomatosis with polyangiitis (gpa; formerly known as wegener's granulomatosis), microscopic polyangiitis (mpa), and eosinophilic granulomatosis with polyangiitis (egpa; previously known as churg-strauss syndrome); has received 3 or 4 doses of an mrna vaccine; age 18 years and older; male or non-pregnant female; rituximab treatment within last 12 months; able to comprehend the study protocol and provide informed consent. exclusion criteria any medical disease or condition that, in the opinion of the site principal investigator or sub-investigator, precludes study participation; significant behavioral disturbances; previous diagnosis of hepatitis b, hepatitis c or hiv; acute illness, with or without fever within 72 hours prior to vaccination; history of hypersensitivity or severe allergic reaction such as anaphylaxis to a component of the vaccine or to a previous vaccine; any vaccine received in the 30 days prior to the fourth or fifth dose of covid-19 vaccine; any vaccine scheduled to be received in the 30 days following the administration of the fourth or fifth dose of covid-19 vaccine and that cannot be postponed; people who experienced inflammation of the heart or lining of the heart (myocarditis or pericarditis) after a previous dose of an mrna vaccine or protein subunit vaccine. ne;

inclusion criteria: systemic autoimmune rheumatic disease diagnosed by a rheumatologist at chu de quebec - université laval, mcgill university health centre, jewish general hospital or centre hospitalier de l'université de montréal has received 3 doses of an mrna vaccine age 18 years and older male or non-pregnant female rituximab or anti-cd-20mab treatment within last 12mo able to comprehend the study protocol and provide informed consent

inclusion criteria: systemic autoimmune rheumatic disease diagnosed by a rheumatologist at chu de quebec - université laval, mcgill university health centre, jewish general hospital or centre hospitalier de l'université de montréal has received 3 doses of an mrna vaccine age 18 years and older male or non-pregnant female rituximab or anti-cd-20mab treatment within last 12mo able to comprehend the study protocol and provide informed consent